This file contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this file.
This file is provided for convenience purposes only. Reliance shall only be placed on the published investor news and the figures contained therein.
Income
< back to overview
Statement of Comprehensive Income (IFRS, unaudited)
€ in millions
Q2/2022
Q2/2021
Growth
H1/2022
H1/2021
Growth
Sales
10,018
9,246
8%
19,738
18,230
8%
Costs of sales
-7,340
-6,628
-11%
-14,502
-13,154
-10%
Gross profit
2,678
2,618
2%
5,236
5,076
3%
Selling, general and administrative expenses
-1,631
-1,400
-17%
-3,108
-2,666
-17%
Research and development expenses
-202
-197
-3%
-381
-383
1%
Operating income (EBIT)
845
1,021
-17%
1,747
2,027
-14%
Interest result
-116
-121
4%
-234
-258
9%
Financial result
-116
-121
4%
-234
-258
9%
Income before income taxes
729
900
-19%
1,513
1,769
-14%
Income taxes
-165
-192
14%
-350
-390
10%
Net income
564
708
-20%
1,163
1,379
-16%
Less noncontrolling interests
-181
-237
24%
-367
-473
22%
Net income attributable to Fresenius SE & Co. KGaA1,2
450
475
-5%
913
911
0%
Net income attributable to Fresenius SE & Co. KGaA1
383
471
-19%
796
906
-12%
Earnings per ordinary share (€)1,2
0.80
0.85
-6%
1.63
1.63
0%
Fully diluted earnings per ordinary share (€)1,2
0.80
0.85
-6%
1.63
1.63
0%
Earnings per ordinary share (€)1
0.68
0.84
-19%
1.42
1.62
-12%
Fully diluted earnings per ordinary share (€)1
0.68
0.84
-19%
1.42
1.62
-12%
Average number of shares
560,080,521
557,771,093
0%
559,291,332
557,656,126
0%
EBITDA2
1,682
1,674
0%
3,344
3,305
1%
Depreciation and amortization2
679
641
6%
1,341
1,263
6%
EBIT2
1,003
1,033
-3%
2,003
2,042
-2%
EBITDA margin2
16.8%
18.1%
16.9%
18.1%
EBIT margin2
10.0%
11.2%
10.1%
11.2%
1 Net income attributable to Fresenius SE & Co. KGaA
2 Before special items
Reconciliation Group
< back to overview
Consolidated results for Q2/2022 and H1/2022 as well as for Q2/2021 and H1/2021 include special items. These concern: Revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program (including costs related to FME25 program), impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties as well as remeasurement Humacyte investment. The special items shown within the reconciliation tables are reported in the "Corporate" segment.
Consolidated results for Q2/2022 and H1/2022 as well as for Q2/2021 and H1/2021 include special items. These concern: Revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program (including costs related to FME25 program), impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties as well as remeasurement Humacyte investment. The special items shown within the reconciliation tables are reported in the "Corporate" segment.
Fresenius Group
Fresenius Group
€ in millions
Q2/22
Q2/21
Growth rate
Growth rate (cc)
€ in millions
H1/22
H1/21
Growth rate
Growth rate (cc)
Sales reported
10,018
9,246
8%
3%
Sales reported
19,738
18,230
8%
4%
EBIT reported (after special items)
845
1,021
-17%
-23%
EBIT reported
1,747
2,027
-14%
-18%
Revaluations of biosimilars contingent purchase price liabilities
-
-
Revaluations of biosimilars contingent purchase price liabilities
-2
-
Expenses associated with the Fresenius cost and efficiency program
50
12
Expenses associated with the Fresenius cost and efficiency program
114
15
Impacts related to the war in Ukraine
10
-
Impacts related to the war in Ukraine
40
-
Transaction costs mAbxience, Ivenix
5
-
Transaction costs mAbxience, Ivenix
7
-
Hyperinflation Turkey
10
-
Hyperinflation Turkey
10
-
Retroactive duties
9
-
Retroactive duties
9
-
Remeasurement Humacyte investment
74
-
Remeasurement Humacyte investment
78
-
EBIT (before special items)
1,003
1,033
-3%
-9%
EBIT (before special items)
2,003
2,042
-2%
-7%
Net interest reported (after special items)
-116
-121
4%
10%
Net interest reported
-234
-258
9%
14%
Revaluations of biosimilars contingent purchase price liabilities
-
-
Revaluations of biosimilars contingent purchase price liabilities
-1
-
Net interest (before special items)
-116
-121
4%
10%
Net interest (before special items)
-235
-258
9%
13%
Income taxes reported (after special items)
-165
-192
14%
19%
Income taxes reported (after special items)
-350
-390
10%
14%
Revaluations of biosimilars contingent purchase price liabilities
-
-
Revaluations of biosimilars contingent purchase price liabilities
1
-
Expenses associated with the Fresenius cost and efficiency program
-14
-4
Expenses associated with the Fresenius cost and efficiency program
-26
-5
Impacts related to the war in Ukraine
-1
-
Impacts related to the war in Ukraine
-4
-
Transaction costs mAbxience, Ivenix
-1
-
Transaction costs mAbxience, Ivenix
-1
-
Hyperinflation Turkey
0
-
Hyperinflation Turkey
0
-
Retroactive duties
-3
-
Retroactive duties
-3
-
Remeasurement Humacyte investment
-20
-
Remeasurement Humacyte investment
-21
-
Income taxes (before special items)
-204
-196
-4%
3%
Income taxes (before special items)
-404
-395
-2%
3%
Noncontrolling interests reported (after special items)
-181
-237
24%
32%
Noncontrolling interests reported (after special items)
-367
-473
22%
28%
Expenses associated with the Fresenius cost and efficiency program
-9
-4
Expenses associated with the Fresenius cost and efficiency program
-26
-5
Impacts related to the war in Ukraine
-3
-
Impacts related to the war in Ukraine
-16
-
Hyperinflation Turkey
-4
-
Hyperinflation Turkey
-4
-
Remeasurement Humacyte investment
-36
-
Remeasurement Humacyte investment
-38
-
Noncontrolling interests (before special items)
-233
-241
3%
12%
Noncontrolling interests (before special items)
-451
-478
6%
12%
Net income reported (after special items)1
383
471
-19%
-24%
Net income reported (after special items)1
796
906
-12%
-16%
Revaluations of biosimilars contingent purchase price liabilities
-
-
Revaluations of biosimilars contingent purchase price liabilities
-2
-
Expenses associated with the Fresenius cost and efficiency program
27
4
Expenses associated with the Fresenius cost and efficiency program
62
5
Impacts related to the war in Ukraine
6
-
Impacts related to the war in Ukraine
20
-
Transaction costs mAbxience, Ivenix
4
-
Transaction costs mAbxience, Ivenix
6
-
Hyperinflation Turkey
6
-
Hyperinflation Turkey
6
-
Retroactive duties
6
-
Retroactive duties
6
-
Remeasurement Humacyte investment
18
-
Remeasurement Humacyte investment
19
-
Net income (before special items)1
450
475
-5%
-10%
Net income (before special items)1
913
911
0%
-4%
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Reconciliation FMC
< back to overview
Fresenius Medical Care
Fresenius Medical Care
in € millions
Q2/22
Q2/21
Growth rate
Growth rate (cc)
in € millions
H1/22
H1/21
Growth rate
Growth rate (cc)
Sales reported
4,757
4,320
10%
1%
Sales reported
9,305
8,530
9%
2%
EBIT reported (after special items)
341
424
-20%
-27%
EBIT reported (after special items)
688
898
-23%
-29%
Costs related to FME25 program
21
9
Costs related to FME25 program
57
12
Impacts related to the war in Ukraine
2
-
Impacts related to the war in Ukraine
23
-
Hyperinflation Turkey
6
-
Hyperinflation Turkey
6
-
Remeasurement Humacyte investment
75
-
Remeasurement Humacyte investment
78
-
EBIT (before special items)
445
433
3%
-6%
EBIT (before special items)
852
910
-6%
-13%
Net income reported (after special items)1
147
219
-33%
-39%
Net income reported (after special items)1
305
468
-35%
-39%
Costs related to FME25 program
15
6
Costs related to FME25 program
40
8
Impacts related to the war in Ukraine
2
-
Impacts related to the war in Ukraine
20
-
Hyperinflation Turkey
6
-
Hyperinflation Turkey
6
-
Remeasurement Humacyte investment
55
-
Remeasurement Humacyte investment
57
-
Net income (before special items)1
225
225
0%
-7%
Net income (before special items)1
428
476
-10%
-15%
1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
1 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
Reconciliation Kabi
< back to overview
Fresenius Kabi
Fresenius Kabi
€ in millions
Q2/22
Q2/21
Growth rate
Growth rate (cc)
€ in millions
H1/22
H1/21
Growth rate
Growth rate (cc)
Sales reported
1,896
1,755
8%
2%
Sales reported
3,743
3,516
6%
1%
Revaluations of biosimilars contingent purchase price liabilities
-
-
Revaluations of biosimilars contingent purchase price liabilities
-2
-
Expenses associated with the Fresenius cost and efficiency program
18
-
Expenses associated with the Fresenius cost and efficiency program
46
-
Impacts related to the war in Ukraine
4
-
Impacts related to the war in Ukraine
12
-
Transaction costs mAbxience, Ivenix
5
-
Transaction costs mAbxience, Ivenix
7
-
Hyperinflation Turkey
4
-
Hyperinflation Turkey
4
-
EBIT (before special items)
271
298
-9%
-17%
EBIT (before special items)
564
574
-2%
-9%
Reconciliation Helios
< back to overview
Fresenius Helios
Fresenius Helios
€ in millions
Q2/22
Q2/21
Growth rate
Growth rate (cc)
€ in millions
H1/22
H1/21
Growth rate
Growth rate (cc)
Sales reported
2,925
2,738
7%
6%
Sales reported
5,856
5,387
9%
8%
EBIT reported (after special items)
303
298
2%
1%
EBIT reported (after special items)
609
566
8%
7%
Expenses associated with the Fresenius cost and efficiency program
0
-
Expenses associated with the Fresenius cost and efficiency program
0
-
EBIT (before special items)
303
298
2%
1%
EBIT (before special items)
609
566
8%
7%
Reconciliation Vamed
< back to overview
Fresenius Helios
Fresenius Helios
€ in millions
Q2/22
Q2/21
Growth rate
Growth rate (cc)
€ in millions
H1/22
H1/21
Growth rate
Growth rate (cc)
Sales reported
562
556
1%
1%
Sales reported
1,075
1,033
4%
3%
EBIT reported (after special items)
5
16
-69%
-69%
EBIT reported (after special items)
12
12
0%
0%
Expenses associated with the Fresenius cost and efficiency program
1
-
Expenses associated with the Fresenius cost and efficiency program
2
-
Impacts related to the war in Ukraine
5
-
Impacts related to the war in Ukraine
5
-
EBIT (before special items)
11
16
-31%
-31%
EBIT (before special items)
19
12
58%
58%
Reconciliation Corporate
< back to overview
Fresenius Corporate
Fresenius Corporate
€ in millions
Q2/22
Q2/21
Growth rate
Growth rate (cc)
€ in millions
H1/22
H1/21
Growth rate
Growth rate (cc)
Expenses associated with the Fresenius cost and efficiency program
7
3
Expenses associated with the Fresenius cost and efficiency program
9
3
Retroactive duties
9
-
Retroactive duties
9
-
EBIT (before special items)
-27
-12
-125%
-125%
EBIT (before special items)
-41
-20
-105%
-110%
Covid-19-effects
< back to overview
Estimated COVID-19 effects Q2/2021
Growth cc
Estimated
Estimated Growth cc
as reported
COVID impact cc
incl. COVID-19
excl. COVID-19
€m
Q2/22
Q2/21
Q2/22
Q2/21
Q2/22
Q2/21
Sales
3%
8%
1% to 0%
2% to 1%
2% to 3%
6% to 7%
Net income before special items1
-10%
20%
6% to 2%
10% to 6%
-16% to -12%
10% to 14%
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Estimated COVID-19 effects H1/2021
Growth cc
Estimated
Estimated Growth cc
as reported
COVID impact cc
incl. COVID-19
excl. COVID-19
€m
H1/22
H1/21
H1/22
H1/21
H1/22
H1/21
Sales
4%
6%
0% to -1%
1% to 0%
4% to 5%
5% to 6%
Net income before special items1
-4%
8%
6% to 2%
4% to 0%
-10% to -6%
4% to 8%
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Basis for guidance
< back to overview
Fresenius Group/ Fresenius Medical Care / Fresenius Kabi / Fresenius Helios / Fresenius Vamed
Base for Guidance 2022
€ in millions
Fresenius Group
Fresenius Medical Care
Fresenius Kabi
Fresenius Helios
Fresenius Vamed
Sales reported (base)
37,520
17,619
7,193
10,891
2,297
Revaluations of biosimilars contingent purchase price liabilities
-49
Expenses associated with the Fresenius cost and efficiency program
58
10
0
EBIT (before special items) = base Kabi, Helios, Vamed guidance
1,153
1,127
101
Net income (as reported)
1,818
969
Revaluations of biosimilars contingent purchase price liabilities
-33
Costs related to FME25 program
49
Expenses associated with the Fresenius cost and efficiency program
82
Net income (before special items) = base FMC guidance
1,018
Net income (before special items) = base Fresenius Group guidance
1,867
Balance sheet
< back to overview
€ in millions
June 30, 2022
December 31, 2021
Change
Assets
Current assets
18,818
17,461
8%
thereof trade accounts receivables
7,858
7,045
12%
thereof inventories
4,697
4,218
11%
thereof cash and cash equivalents
2,129
2,764
-23%
Non-current assets
57,294
54,501
5%
thereof property, plant and equipment
12,943
12,569
3%
thereof goodwill and other intangible assets
34,935
32,774
7%
thereof right-of-use-assets
6,238
6,014
4%
Total assets
76,112
71,962
6%
Liabilities and shareholders' equity
Liabilities
44,079
42,674
3%
thereof trade accounts payable
1,929
2,039
-5%
thereof accruals and other short-term liabilities
10,542
10,594
0%
thereof debt
28,368
27,155
4%
thereof lease liabilities
6,858
6,590
4%
Noncontrolling interests
11,369
10,290
10%
Total Fresenius SE & Co. KGaA shareholders' equity
20,664
18,998
9%
Total shareholders' equity
32,033
29,288
9%
Total liabilities and shareholders' equity
76,112
71,962
6%
Cash Flow
< back to overview
Statement of Cash Flows (IFRS, unaudited)
€ in millions
Q2/2022
Q2/2021
Growth
H1/2022
H1/2021
Growth
Net income
564
708
-20%
1,163
1,379
-16%
Depreciation and amortization
683
641
7%
1,376
1,263
9%
Change in working capital and others
-230
102
--
-1,421
-539
-164%
Operating cash flow
1,017
1,451
-30%
1,118
2,103
-47%
Capital expenditure, net
-436
-499
13%
-792
-910
13%
Cash flow before acquisitions and dividends
581
952
-39%
326
1,193
-73%
Cash used for acquisitions, net
-271
-456
41%
-363
-519
30%
Dividends paid
-701
-855
18%
-757
-916
17%
Free cash flow after acquisitions and dividends
-391
-359
-9%
-794
-242
--
Cash provided by/used for financing activities
408
711
-43%
89
588
-85%
Effect of exchange rates on change in cash and cash equivalents
35
21
67%
70
67
4%
Net change in cash and cash equivalents
52
373
-86%
-635
413
--
Segment Reporting Q2
< back to overview
Segment reporting by business unit Q2/2022 (IFRS, unaudited)
Fresenius Medical Care
Fresenius Kabi
Fresenius Helios
Fresenius Vamed
Corporate
Fresenius Group
€ in millions
Q2/22
1
Q2/21
2
Growth
Q2/22
3
Q2/21
Growth
Q2/22
4
Q2/21
Growth
Q2/22
5
Q2/21
Growth
Q2/22
6
Q2/21
7
Growth
Q2/22
Q2/21
Growth
Sales
4,757
4,320
10%
1,896
1,755
8%
2,925
2,738
7%
562
556
1%
-122
-123
1%
10,018
9,246
8%
thereof contribution to consolidated sales
4,740
4,308
10%
1,878
1,739
8%
2,918
2,732
7%
481
466
3%
1
1
0%
10,018
9,246
8%
thereof intercompany sales
17
12
42%
18
16
13%
7
6
17%
81
90
-10%
-123
-124
1%
-
-
contribution to consolidated sales
47%
47%
19%
19%
29%
29%
5%
5%
0%
0%
100%
100%
EBITDA
866
829
5%
379
406
-7%
429
413
4%
35
38
-8%
-181
-24
--
1,528
1,662
-8%
Depreciation and amortization
421
396
7%
108
108
0%
126
115
10%
24
22
9%
4
0
--
683
641
7%
EBIT
445
433
3%
271
298
-9%
303
298
2%
11
16
-31%
-185
-24
--
845
1,021
-17%
Net interest
-72
-69
-3%
-9
-16
44%
-45
-45
0%
-1
-1
0%
11
10
10%
-116
-121
4%
Income taxes
-91
-77
-15%
-58
-59
2%
-57
-54
-6%
-3
-3
0%
44
1
--
-165
-192
14%
Net income attributable to shareholders of Fresenius SE & Co. KGaA
225
225
0%
189
204
-7%
197
193
2%
6
11
-45%
-234
-162
-44%
383
471
-19%
Operating cash flow
751
921
-18%
109
197
-45%
194
223
-13%
7
58
-88%
-44
52
-185%
1,017
1,451
-30%
Cash flow before acquisitions and dividends
582
720
-19%
-1
83
-101%
48
70
-31%
-2
33
-106%
-46
46
-200%
581
952
-39%
Capital expenditure
172
210
-18%
102
117
-13%
134
154
-13%
8
25
-68%
3
3
0%
419
509
-18%
Acquisitions
67
79
-14%
220
-
3
412
-99%
-
0
-100%
1
-
291
491
-41%
Research and development expenses
55
52
7%
147
144
2%
1
1
0%
-
-
-1
0
--
202
197
3%
Key figures
EBITDA margin
18.2%
19.2%
20.0%
23.1%
14.7%
15.1%
6.2%
6.8%
16.8%
8
18.1%
4
EBIT margin
9.4%
10.0%
14.3%
17.0%
10.4%
10.9%
2.0%
2.9%
10.0%
8
11.2%
4
Depreciation and amortization in % of sales
8.9%
9.2%
5.7%
6.2%
4.3%
4.2%
4.3%
4.0%
6.8%
6.9%
Operating cash flow in % of sales
15.8%
21.3%
5.7%
11.2%
6.6%
8.1%
1.2%
10.4%
10.2%
15.7%
1 Before costs related to FME25 program, impacts related to the war in Ukraine, hyperinflation Turkey and remeasurement Humacyte investment
2 Before costs related to FME25 program
3 Before expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix and hyperinflation Turkey
4 Before expenses associated with the Fresenius cost and efficiency program
5 Before expenses associated with the Fresenius cost and efficiency program and impacts related to the war in Ukraine
6 After expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
7 After expenses associated with the Fresenius cost and efficiency program
8 Before expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
Segment Reporting H1
< back to overview
Segment reporting by business unit H1/2022 (IFRS, unaudited)
Fresenius Medical Care
Fresenius Kabi
Fresenius Helios
Fresenius Vamed
Corporate
Fresenius Group
€ in millions
H1/22
2
H1/21
3
Growth
H1/22
4
H1/21
Growth
H1/22
5
H1/21
Growth
H1/22
6
H1/21
Growth
H1/22
7
H1/21
8
Growth
H1/22
H1/21
Growth
Sales
9,305
8,530
9%
3,743
3,516
6%
5,856
5,387
9%
1,075
1,033
4%
-241
-236
-2%
19,738
18,230
8%
thereof contribution to consolidated sales
9,274
8,507
9%
3,707
3,484
6%
5,844
5,375
9%
912
863
6%
1
1
0%
19,738
18,230
8%
thereof intercompany sales
31
23
35%
36
32
13%
12
12
0%
163
170
-4%
-242
-237
-2%
-
-
contribution to consolidated sales
47%
47%
19%
19%
29%
29%
5%
5%
0%
0%
100%
100%
EBITDA
1,686
1,694
0%
775
780
-1%
857
793
8%
67
55
22%
-262
-32
--
3,123
3,290
-5%
Depreciation and amortization
834
784
6%
211
206
2%
248
227
9%
48
43
12%
35
3
--
1,376
1,263
9%
EBIT
852
910
-6%
564
574
-2%
609
566
8%
19
12
58%
-297
-35
--
1,747
2,027
-14%
Net interest
-141
-145
3%
-20
-33
39%
-93
-89
-4%
-3
-4
25%
23
13
77%
-234
-258
9%
Income taxes
-171
-172
2%
-120
-118
-2%
-115
-102
-13%
-4
-2
-100%
60
4
--
-350
-390
10%
Net income attributable to shareholders of Fresenius SE & Co. KGaA
428
476
-10%
390
394
-1%
392
366
7%
10
4
150%
-424
-334
-27%
796
906
-12%
Operating cash flow
910
1,129
-19%
242
475
-49%
58
438
-87%
-38
14
--
-54
47
--
1,118
2,103
-47%
Cash flow before acquisitions and dividends
581
749
-22%
38
229
-83%
-179
208
-186%
-56
-33
-70%
-58
40
--
326
1,193
-73%
Total assets1
36,070
34,367
5%
15,855
14,698
8%
21,593
20,891
3%
2,906
2,795
4%
-312
-789
60%
76,112
71,962
6%
Debt1
13,659
13,320
3%
4,346
4,159
4%
8,214
8,059
2%
830
721
15%
1,319
896
47%
28,368
27,155
4%
Other operating liabilities1
6,024
6,199
-3%
3,386
3,250
4%
3,406
3,176
7%
1,009
994
2%
118
385
-69%
13,943
14,004
0%
Capital expenditure
334
394
-15%
186
216
-14%
213
230
-7%
20
47
-57%
4
6
-33%
757
893
-15%
Acquisitions
150
210
-28%
222
1
--
75
429
-83%
6
0
--
-
-
453
640
-29%
Research and development expenses
105
101
4%
275
281
-2%
1
2
-50%
-
-
0
-1
100%
381
383
-1%
Employees (per capita on balance sheet date)1
130,448
130,251
0%
42,186
41,397
2%
125,101
123,484
1%
19,781
19,721
0%
1,131
1,225
-8%
318,647
316,078
1%
Key figures
EBITDA margin
18.1%
19.9%
20.7%
22.2%
14.6%
14.7%
6.2%
5.3%
16.9%
9
18.1%
5
EBIT margin
9.2%
10.7%
15.1%
16.3%
10.4%
10.5%
1.8%
1.2%
10.1%
9
11.2%
5
Depreciation and amortization in % of sales
9.0%
9.2%
5.6%
5.9%
4.2%
4.2%
4.5%
4.2%
7.0%
6.9%
Operating cash flow in % of sales
9.8%
13.2%
6.5%
13.5%
1.0%
8.1%
-3.5%
1.4%
5.7%
11.5%
ROOA1
5.5%
6.2%
8.7%
9.4%
5.9%
5.9%
4.4%
4.3%
6.1%
10
6.5%
11
1 2021: December 31
2 Before costs related to FME25 program, impacts related to the war in Ukraine, hyperinflation Turkey and remeasurement Humacyte investment
3 Before costs related to FME25 program
4 Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix and hyperinflation Turkey
5 Before expenses associated with the Fresenius cost and efficiency program
6 Before expenses associated with the Fresenius cost and efficiency program and impacts related to the war in Ukraine
7 After revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
8 After expenses associated with the Fresenius cost and efficiency program
9 Before revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment
10 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities, expenses associated with the Fresenius cost and efficiency program, impacts related to the war in Ukraine, transaction costs mAbxience, Ivenix, hyperinflation Turkey, retroactive duties and remeasurement Humacyte investment.
11 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities and expenses associated with the Fresenius cost and efficiency program.
Sales by business segment
< back to overview
Sales by business segment
€ in millions
Q2/22
Q2/21
Growth
Currency translation effects
Growth at constant rates
Organic sales growth
Acquisitions
Divestitures/Others
% of total sales1
Fresenius Medical Care
4,757
4,320
10%
9%
1%
0%
1%
0%
47%
Fresenius Kabi
1,896
1,755
8%
6%
2%
2%
0%
0%
19%
Fresenius Helios
2,925
2,738
7%
1%
6%
5%
1%
0%
29%
Fresenius Vamed
562
556
1%
0%
1%
1%
1%
-1%
5%
Total
10,018
9,246
8%
5%
3%
2%
1%
0%
100%
1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.
€ in millions
H1/22
H1/21
Growth
Currency translation effects
Growth at constant rates
Organic sales growth
Acquisitions
Divestitures/Others
% of total sales1
Fresenius Medical Care
9,305
8,530
9%
7%
2%
1%
1%
0%
47%
Fresenius Kabi
3,743
3,516
6%
5%
1%
1%
0%
0%
19%
Fresenius Helios
5,856
5,387
9%
1%
8%
6%
2%
0%
29%
Fresenius Vamed
1,075
1,033
4%
1%
3%
4%
0%
-1%
5%
Total
19,738
18,230
8%
4%
4%
3%
1%
0%
100%
1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.
Sales by region
< back to overview
Sales by region
€ in millions
Q2/22
Q2/21
Growth
Currency translation effects
Growth at constant rates
Organic growth
Acquisitions
Divestitures/Others
% of total sales
North America
3,916
3,486
12%
13%
-1%
-1%
1%
-1%
39%
Europe
4,430
4,229
5%
0%
5%
4%
1%
-0%
44%
Asia-Pacific
1,004
961
4%
6%
-2%
-2%
0%
0%
10%
Latin America
531
453
17%
7%
10%
8%
2%
0%
5%
Africa
137
117
17%
0%
17%
17%
0%
0%
2%
Total
10,018
9,246
8%
5%
3%
2%
1%
0%
100%
€ in millions
H1/22
H1/21
Growth
Currency translation effects
Growth at constant rates
Organic growth
Acquisitions
Divestitures/Others
% of total sales
North America
7,675
6,929
11%
10%
1%
-1%
1%
1%
39%
Europe
8,811
8,340
6%
0%
6%
5%
1%
-0%
45%
Asia-Pacific
2,008
1,881
7%
6%
1%
1%
0%
0%
10%
Latin America
1,003
875
15%
5%
10%
8%
2%
0%
5%
Africa
241
205
18%
2%
16%
16%
0%
0%
1%
Total
19,738
18,230
8%
4%
4%
3%
1%
0%
100%
Attachments
Original Link
Original Document
Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 02 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2022 06:29:02 UTC.
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows:
- dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).